Zhongguancun announced that Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of the company, recently received the “Notice of Acceptance” issued by the State Drug Administration. The registration and marketing license applications for drugs produced in the country were accepted. The acceptance numbers were CYHS2601851 and CYHS2601850, respectively, and the registration classification is 4 types of chemicals. This drug is suitable for patients with gout and hyperuricemia. The original drug was the only highly selective URAT1 inhibitor approved for marketing in the world. It was approved for marketing in China in December 2024.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.